NanOlogy touted results today from preclinical studies of its inhaled submicron particle formulation of paclitaxel, NanoPac.
The company said animal studies have shown prolonged retention of the cancer drug in lung tissue and significant tumor regression without adverse drug-related side effects.
NanOlogy plans to present the data from its preclinical studies at this year’s annual meeting of the American Society of Clinical Oncology in Chicago.
In a preclinical pharmacokinetic study, researchers examined how well NanoPac was retained following a single inhalation via a nose-only exposure chamber and found measurable amounts of the drug in the rat’s lung tissue at the end of the 14-day study.
Histologic analysis of a model treated with the inhaled NanoPac found that the drug resulted in a significant decrease in primitive tumor cell population and significant tumor regression, the company reported.
“In our initial PK study, inhaled NanoPac resulted in longer lung retention of drug at a higher concentration compared to systemically administered paclitaxel. The evidence seen in our preclinical PK and efficacy studies has given us the confidence to move forward with IND-enabling studies in preparation for clinical trials,” Dr. Gere diZerega, VP of medical affairs, said in prepared remarks.